Abstract Number: L01 • 2018 ACR/ARHP Annual Meeting
New Cardiovascular Events in Patients with Gout Treated with Xanthine-Oxidase Inhibitors: An Inception Cohort Analysis
Background/Purpose: The recent CARES trial findings have contributed to the controversy around the development of cardiovascular (CV) events in gouty patients using febuxostat (FBX). In…Abstract Number: L05 • 2018 ACR/ARHP Annual Meeting
Treatment-Naïve, Early Rheumatoid Arthritis Patients Demonstrate Reversible Abnormalities of Vascular Function on Cardiac MRI with RA Therapy with Preliminary Suggestion of Greater Improvement with Anti-TNF Compared to MTX/Conventional Therapy – a First, RCT Derived Longitudinal Study
Background/Purpose: We previously reported abnormal cardiac MRI (CMR)-determined aortic stiffness in patients with early, treatment-naive RA1,2. We now report on whether this vascular stiffness is…Abstract Number: 471 • 2018 ACR/ARHP Annual Meeting
Early Signs of Diastolic Impairment in Children with Incident Systemic Lupus Erythematosus
Background/Purpose: The timing and etiology of diastolic impairment in pediatric-onset systemic lupus erythematosus (pSLE) are poorly understood, and the role of screening echocardiography remains unclear.…Abstract Number: 682 • 2018 ACR/ARHP Annual Meeting
Nonsteroidal Anti-Inflammatory Drug Use and Hypertension in Ankylosing Spondylitis
Background/Purpose: Cardiovascular morbidity and mortality are increased in Ankylosing Spondylitis (AS). Nonsteroidal anti-inflammatory drugs (NSAIDs) are the first line pharmacological therapy in AS; however, their…Abstract Number: 1100 • 2018 ACR/ARHP Annual Meeting
The Frequencies and Molecular Profiles of CD16+ Monocyte Subsets in Patients with Systemic Lupus Erythematosus, Primary Antiphospholipid Syndrome, and Antiphospholipid Syndrome with Lupus, Identify Specific Clinical Features of These Diseases
Background/Purpose: This study, developed within the IMI-JU project PRECISESADS framework, aimed to determine the enrichment on CD14+ and CD16+ monocyte subpopulations in SLE, APS and…Abstract Number: 1729 • 2018 ACR/ARHP Annual Meeting
Increased Risk of Valvular Heart Disease in Patients with Systemic Sclerosis: Results from a Population-Based Cohort (1980-2016)
Background/Purpose: Systemic Sclerosis (SSc) is a complex, heterogenous autoimmune disease characterized by microvascular injury and widespread fibrosis of the skin and internal organs, particularly lungs…Abstract Number: 2498 • 2018 ACR/ARHP Annual Meeting
The Association of Vitamin D with the Lipid Profile in Rheumatoid Arthritis: An Interplay Among Genetic Polymorphisms, DHCR7 Levels and Seasonality
Background/Purpose: Vitamin D deficiency is a common hallmark of rheumatic diseases, and some controversy exists about its effect on rheumatoid arthritis (RA), in particular about…Abstract Number: 472 • 2018 ACR/ARHP Annual Meeting
Libman Sacks Endocarditis in Pediatric Systemic Lupus Erythematosus: Clinical Features and Complications
Background/Purpose: Libman-Sacks endocarditis (LSE) is a rare manifestation of pediatric-onset systemic lupus erythematosus (pSLE). It is difficult to differentiate LSE from infective endocarditis (IE) in immunosuppressed…Abstract Number: 706 • 2018 ACR/ARHP Annual Meeting
Increased Incidence and Prevalance of Resistant Hypertension in Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study
Background/Purpose: Resistant hypertension (RHTN) is associated with increased risk of cardiovascular events in the general population. Patients with systemic lupus erythematous (SLE) have increased cardiovascular…Abstract Number: 1128 • 2018 ACR/ARHP Annual Meeting
Impact of Urate-Lowering Therapy on the Risk of Cardiovascular Events and All-Cause Mortality Among Individuals with Gout
Background/Purpose: Gout results from an increased body pool of urate that occurs with hyperuricemia. Although urate-lowering therapy (ULT) is beneficial to prevent gout attack, current…Abstract Number: 1744 • 2018 ACR/ARHP Annual Meeting
Prognostic Value of Right Heart Involvement in Systemic Sclerosis:Not Only Pulmonary Arterial Hypertension
Background/Purpose: In SSc, cardiac dysfunction is associated with poor prognosis. Right ventricular involvement is frequently secondary to PAH. Echocardiography is the routine imaging tool to…Abstract Number: 2631 • 2018 ACR/ARHP Annual Meeting
Hydroxychloroquine Blood Levels Are Significantly Associated with Cardiovascular Risk Factors
Background/Purpose: In studies of SLE patients, the benefits of hydroxychloroquine (HCQ) extend beyond control of disease activity. In particular, HCQ use has decreased multiple cardiovascular…Abstract Number: 494 • 2018 ACR/ARHP Annual Meeting
Arterial Wall Inflammation Declines after 6 Months of Anti-Inflammatory Therapy with Methotrexate and/or Adalimumab in Rheumatoid Arthritis Patients
Background/Purpose: Patients with rheumatoid arthritis (RA) have an elevated cardiovascular (CV) disease risk, mostly explained by both an increased prevalence of traditional CV risk factors…Abstract Number: 722 • 2018 ACR/ARHP Annual Meeting
Increased Blood Pressure Visit-to-Visit Variability in Patients with Systemic Lupus Erythematosus: Association with Inflammation, Comorbidities and Increased Mortality
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have increased mortality compared to the general population. As outcomes related to disease control have improved, this mortality…Abstract Number: 1140 • 2018 ACR/ARHP Annual Meeting
Cause-Specific Mortality in Knee, Hip and Hand Osteoarthritis
Background/Purpose: All-cause mortality in osteoarthritis (OA) is reported to be increased. However, the knowledge about cause-specific mortality in OA is still very limited. Thus, our…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 38
- Next Page »